Truong QA, et al. - In this study with 92 patients (age 66 ± 13 years; 80% male; left ventricular ejection fraction 26% ± 7%), researchers investigated how cardiac resynchronization therapy (CRT) outcomes were influenced by cardiorenal status using a dual-marker strategy with amino-terminal pro–brain natriuretic peptide (NT-proBNP) and cystatin C. At CRT implantation and at 1 month, they assessed NT-proBNP and cystatin C levels; categories of CRT patients were defined at 1 month. They assessed 6-month clinical and echocardiographic CRT response and 2 -year major adverse cardiovascular events. Findings revealed that high-risk CRT patients could be detected by assessing cardiorenal status by NT-proBNP and cystatin C, and worse prognosis was observed among those with elevated concentrations of both.